Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,472
Recruiting: 1,283
Ph III recruiting: 130
Growth YoY: +4.1%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,642)

clinicaltrialsPublishedShowing 401–450 of 4,946 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04320888	Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial	active not recruiting	Phase 2	1	National Cancer Institute (NCI)NIH	3	Aug 3, 2026	clinicaltrials
NCT07638683	A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).	recruiting	Phase 2	30	Shanghai Zhongshan HospitalOTHER